Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report)’s stock price dropped 4.5% on Friday . The stock traded as low as $8.1950 and last traded at $8.22. Approximately 15,987 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 602,475 shares. The stock had previously closed at $8.61.
Athira Pharma Stock Performance
The firm’s 50 day moving average price is $9.55 and its two-hundred day moving average price is $7.32. The company has a market cap of $32.42 million, a P/E ratio of -0.85 and a beta of 2.79.
Institutional Trading of Athira Pharma
Several hedge funds have recently bought and sold shares of ATHA. Focus Partners Wealth acquired a new stake in Athira Pharma in the 3rd quarter valued at $35,000. Renaissance Technologies LLC grew its position in Athira Pharma by 44.7% in the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after purchasing an additional 23,223 shares during the period. Jane Street Group LLC acquired a new stake in Athira Pharma in the 4th quarter valued at $100,000. Spruce Street Capital LP acquired a new stake in Athira Pharma in the 4th quarter valued at $2,980,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Athira Pharma in the 4th quarter valued at $2,891,000. Institutional investors and hedge funds own 57.12% of the company’s stock.
Athira Pharma Company Profile
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Recommended Stories
- Five stocks we like better than Athira Pharma
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
